Cost-benefit analysis of the hepatitis B vaccination to prevent mother-to-child transmission strategies in China, 1992-2019
10.3760/cma.j.cn112338-20210319-00226
- VernacularTitle:中国1992-2019年乙型肝炎疫苗免疫及母婴阻断策略的成本效益分析
- Author:
Hui ZHENG
1
;
Fuzhen WANG
;
Guomin ZHANG
;
Ning MIAO
;
Xiaofeng LIANG
;
Zundong YIN
Author Information
1. 中国疾病预防控制中心免疫规划中心，北京 100050
- Keywords:
Hepatitis B;
Vaccination;
Mother-to-child transmission;
Cost-benefit analysis
- From:
Chinese Journal of Epidemiology
2021;42(9):1537-1545
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To make a cost-benefit analysis of the hepatitis B vaccination (HepB) to prevent mother-to-child transmission (PMTCT) strategies in China, 1992-2019.Methods:We built a decision analytic-Markov model to estimate the birth cohorts of 1992-2019. The parameters in our model were referred from literature, published yearbooks, and data from Chinese Center for Disease Control and Prevention. We conducted a univariate sensitivity analysis to test the robustness of the model.Results:For the 28 birth cohorts, the Chinese government has invested 37.43 billion RMB Yuan in direct costs and 47.61 billion RMB Yuan in societal costs on HepB vaccination and HBV prevention of mother to child transmission (PMTCT). And we estimated that about 50 million chronic HBV infections and 12.5 million premature deaths due to HBV-related diseases would be averted. China would save 2.89 trillion RMB Yuan and 6.92 trillion RMB Yuan for the direct and societal medical burden on HBV-related conditions. The direct and societal net benefit was 2.85 trillion RMB yuan 6.87 trillion RMB yuan, respectively. The direct and societal benefit-cost ratios (BCRs) were 77.21 and 145.29, respectively.Conclusion:The strategies of HepB vaccination for HBV PMTCT prevention were cost-effective in China during 1992-2019.
